26 research outputs found

    Pathogenesis of Intracranial Aneurysms

    Get PDF
    Introduction: Intracranial aneurysms (IA) are a common neurological problem, the rupture of which frequently constitutes a catastrophic neurological event. While the pathogenesis is largely unknown, it is believed that both genetic and environmental factors work in concert to some degree within patients. Our goal was to take a comprehensive approach to understanding the pathogenesis of IA by identifying factors leading to the formation, growth and rupture of IA. Methods: Since 1994, we have recruited patients and families with IA into the Yale Brain Aneurysm Database. Information regarding aneurysm characteristics (size, location, number), patient characteristics (age, medical, and social history), and family history were recorded. We analyzed this database for environmental factors associated with aneurysmal rupture. Within the same database, we identified and analyzed kindreds with a high IA incidence and penetrance using genome-wide linkage analysis. Collaborations with other centers provided additional kindreds to analyze and confirm our results. Results: Analysis of our database revealed hypertensive patients with IA ≤ 7mm were 2.6 times more likely to rupture (p = .01, 95% CI: 1.21, 5.53) than normotensive patients. Posterior circulation aneurysms were 3.5 times more likely to rupture than anterior circulation aneurysms (p = .048, 95% CI: 0.95, 19.4). Further, genome-wide linkage analysis revealed significant linkage to a single locus, with a lod score of 4.2 at 1p34-36. Conclusions: We identified hypertension, young age, and posterior circulation as significant risk factors for rupture among patients with small aneurysms (≤ 7mm). Additionally, we are the first to map the gene responsible for IA to chromosome 1p34-26

    Safe surgery for glioblastoma: Recent advances and modern challenges.

    Get PDF
    One of the major challenges during glioblastoma surgery is balancing between maximizing extent of resection and preventing neurological deficits. Several surgical techniques and adjuncts have been developed to help identify eloquent areas both preoperatively (fMRI, nTMS, MEG, DTI) and intraoperatively (imaging (ultrasound, iMRI), electrostimulation (mapping), cerebral perfusion measurements (fUS)), and visualization (5-ALA, fluoresceine)). In this review, we give an update of the state-of-the-art management of both primary and recurrent glioblastomas. We will review the latest surgical advances, challenges, and approaches that define the onco-neurosurgical practice in a contemporary setting and give an overview of the current prospective scientific efforts

    The PROGRAM study: awake mapping versus asleep mapping versus no mapping for high-grade glioma resections: study protocol for an international multicenter prospective three-arm cohort study.

    Get PDF
    INTRODUCTION The main surgical dilemma during glioma resections is the surgeon's inability to accurately identify eloquent areas when the patient is under general anaesthesia without mapping techniques. Intraoperative stimulation mapping (ISM) techniques can be used to maximise extent of resection in eloquent areas yet simultaneously minimise the risk of postoperative neurological deficits. ISM has been widely implemented for low-grade glioma resections backed with ample scientific evidence, but this is not yet the case for high-grade glioma (HGG) resections. Therefore, ISM could thus be of important value in HGG surgery to improve both surgical and clinical outcomes. METHODS AND ANALYSIS This study is an international, multicenter, prospective three-arm cohort study of observational nature. Consecutive HGG patients will be operated with awake mapping, asleep mapping or no mapping with a 1:1:1 ratio. Primary endpoints are: (1) proportion of patients with National Institute of Health Stroke Scale deterioration at 6 weeks, 3 months and 6 months after surgery and (2) residual tumour volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: (1) overall survival and (2) progression-free survival at 12 months after surgery; (3) oncofunctional outcome and (4) frequency and severity of serious adverse events in each arm. Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. ETHICS AND DISSEMINATION The study has been approved by the Medical Ethics Committee (METC Zuid-West Holland/Erasmus Medical Center; MEC-2020-0812). The results will be published in peer-reviewed academic journals and disseminated to patient organisations and media. TRIAL REGISTRATION NUMBER ClinicalTrials.gov ID number NCT04708171 (PROGRAM-study), NCT03861299 (SAFE-trial)
    corecore